MR22388, a novel anti-cancer agent with a strong FLT-3 ITD kinase affinity.

@article{Rochais2013MR22388AN,
  title={MR22388, a novel anti-cancer agent with a strong FLT-3 ITD kinase affinity.},
  author={Christophe Rochais and Thierry Cresteil and Vittoria Perri and Marie Jouanne and Aur{\'e}lien Lesnard and Sylvain Rault and Patrick Dallemagne},
  journal={Cancer letters},
  year={2013},
  volume={331 1},
  pages={92-8}
}
This work describes the study of the mechanism of action and spectrum of activity of MR22388, a novel anti-cancer agent belonging to the tripentone series. MR22388 is highly cytotoxic (within the nanomolar range) against numerous cancer cell lines and studies of its cytotoxicity mechanisms show that it is a weak inhibitor of the polymerization of tubulin and that it induces apoptosis via the MAP kinase pathways. Further MR22388 is a very strong inhibitor of several kinases including the… CONTINUE READING

References

Publications referenced by this paper.
Showing 1-10 of 17 references

J

V. Lisowski, S. Léonce, L. Kraus-Berthier
Sopkova-de Oliveira Santos, A. Pierré, G. Atassi, D.-H. Caignard, P. Renard, S. Rault, Design, synthesis, and evaluation of novel thienopyrrolizinones as antitubulin agents, J. Med. Chem. 47 • 2004

Similar Papers

Loading similar papers…